ArticleSpine deformity2026
Use and efficacy of antifibrinolytic agents in patients undergoing growth-friendly surgery for neuromuscular scoliosis.
Article in Spine deformity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is a paucity of data on the use, efficacy, and safety of antifibrinolytic agents (AF) in patients with neuromuscular scoliosis undergoing growth-friendly instrumentation. Previous studies have shown mixed results of AF agents in young patients with neuromuscular conditions, and other authors have expressed concerns regarding adverse effects in this medically fragile population. The purpose of this study was to investigate the rate of use of AF agents for growth-friendly surgery in patients with neuromuscular scoliosis, and assess its impact on blood loss and transfusion requirements.
methodsThis is a retrospective cohort study of patients from a multicenter spine study group with neuromuscular scoliosis that underwent an index growth-friendly procedure. Patients with a history of venous thromboembolism and those undergoing revision surgery or lengthening surgery were excluded. Perioperative data were collected including patient demographics, type of instrumentation, use and type of AF agent, estimated blood loss (EBL), use and volume of cell saver, and intraoperative blood transfusion. Univariate statistics were used to determine differences.
resultsThis study included 335 patients with a mean age of 7 years (SD: 2.6). Of these patients, 176 patients were managed with VEPTR/TGR instrumentation and 159 patients were managed with MCGR instrumentation. AF agents were used in 36% of index cases. In cases with AF use, TXA was the most frequently used agent (TXA:68%, ACA:21%). The use of AF increased over the study period from less than 10% before 2010 to 75% in 2020 (R
conclusionAF agents are being used for patients undergoing growth-friendly procedures with TXA being the most commonly used AF. However, there is no significant difference in EBL, cell saver volume, and intraoperative or postoperative transfusion rates between patients that do or do not receive AF agents for these procedures. Additional studies are needed to validate these results, as well as determine their efficacy, safety, and value in this medically fragile group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.